TY - JOUR
T1 - The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia
T2 - Is It the Same in All Settings?
AU - Elmakaty, Ibrahim
AU - Saglio, Giuseppe
AU - Al-Khabori, Murtadha
AU - Elsayed, Abdelrahman
AU - Elsayed, Basant
AU - Elmarasi, Mohamed
AU - Elsabagh, Ahmed Adel
AU - Alshurafa, Awni
AU - Ali, Elrazi
AU - Yassin, Mohamed
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/2/12
Y1 - 2024/2/12
N2 - Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.
AB - Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.
KW - BCR–ABL1 gene fusion
KW - chronic myeloid leukemia
KW - hematopoietic stem cell transplant
KW - survival
KW - treatment-free remission
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85185948679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185948679&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ec974023-ff1e-3735-89ba-5c6fcb7719f8/
U2 - 10.3390/cancers16040754
DO - 10.3390/cancers16040754
M3 - Review article
C2 - 38398145
AN - SCOPUS:85185948679
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 4
M1 - 754
ER -